Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

BACKGROUND: To examine the effects of the DPP-4i sitagliptin on CV outcomes during and after incident MI in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). METHODS: TECOS randomized 14,671 participants with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Nauck, Michael A., McGuire, Darren K., Pieper, Karen S., Lokhnygina, Yuliya, Strandberg, Timo E., Riefflin, Axel, Delibasi, Tuncay, Peterson, Eric D., White, Harvey D., Scott, Russell, Holman, Rury R.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6719352/
https://ncbi.nlm.nih.gov/pubmed/31481069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0921-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados